Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7246438 | 0.94 | TEAD3 (0.60) | LTA4HGAAMEN1KMT2ATEAD3 | |
| SCHEMBL3891265 | 0.94 | TEAD3 (0.60) | LTA4HGAAMEN1KMT2ATEAD3 | |
| SCHEMBL8108121 | 0.92 | TEAD3 (0.55) | LTA4HGAAMEN1KMT2ATEAD3 | |
| SCHEMBL6944485 | 0.92 | TEAD3 (0.55) | LTA4HGAAMEN1KMT2ATEAD3 | |
| SCHEMBL8109617 | 0.91 | TEAD3 (0.54) | LTA4HGAAMEN1KMT2ATEAD3 | |
| SCHEMBL6941768 | 0.91 | TEAD3 (0.54) | LTA4HGAAMEN1KMT2ATEAD3 | |
| SCHEMBL8108207 | 0.91 | TEAD3 (0.54) | LTA4HGAAMEN1KMT2ATEAD3 | |
| SCHEMBL6941703 | 0.91 | TEAD3 (0.54) | LTA4HGAAMEN1KMT2ATEAD3 | |
| SCHEMBL19557301 | 0.86 | LTA4H (0.75) | LTA4HGAAMEN1KMT2ATEAD3 | |
| SCHEMBL26981197 | 0.86 | LTA4H (0.75) | LTA4HGAAMEN1KMT2ATEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101395150-A | Phenethanolamine derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | CN | disclosed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | LTA4H 470/4885GAA 4107/4885MEN1 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.